We established a quick response research team to monitor the impacts of global pandemic COVID19 on this market to keep our clients informed about latest data and changing strategies. The report will incorporate these insight and data factors. ×
Market Research Report

Global Lupus Therapeutics Market Report by Product, by Distribution Channel, by Gender, & by Region With COVID-19 impact | Forecast Period 2017-2030

Published Date :

2020-09-01

Report Pages :

760

Format :

PDF

Region Covered :

Global

Market Overview

It is anticipated that, the scenario of lupus treatment by 2024 is probably be dominated by AstraZeneca’s anifrolumab, a first-in-class anti-interferon monoclonal antibody (mAb), majorly owing to its virtue in patients with cutaneous and articular action. However, the arrival of new pipeline drugs will serve the requirement for enhanced version of lupus medications, peculiarly for Lupus Nephritis patients, a significant share of patients will remain underserved with methodical medication. The prop of therapeutic options in lupus is provided by off-label therapies that own undesirable safety profiles.

Goldstein Research analyst forecast the Lupus Pipeline Therapeutics Market size is set to reach at a CAGR of 10.5% over the forecast years.

Global Lupus Pipeline Therapeutics Market Segmentation             

By Lupus Type

  • Systemic Lupus Erythematosus (SLE)

  • Lupus Nephritis (LN)

Based on Geography

  • North America (U.S. & Canada) Lupus Pipeline Therapeutics Market

  • Latin America (Brazil, Mexico, Argentina & Rest of Latin America) Lupus Pipeline Therapeutics Market

  • Europe (The U.K., Germany, France, Italy, Spain, Poland, Sweden & RoE) Lupus Pipeline Therapeutics Market

  • Asia-Pacific (China, India, Japan, Singapore, South Korea, Australia, New Zealand, Rest of Asia) Lupus Pipeline Therapeutics Market

  • Middle East & Africa (GCC, South Africa, North Africa, RoMEA) Lupus Pipeline Therapeutics Market

Market Share by Lupus Pipeline Therapeutics Product Type & Geography

According to our global market study on the basis of extensive primary and secondary research:  “One trend is that owing to the great heterogeneity inherent to Lupus, no single approach should be expected to be effective in all patients. Understanding of the pathogenic mechanisms of Lupus continues to expand; additional therapeutic targets and approaches will undoubtedly be identified and should be fully exploited.”

Based on geography, North America and Europe lead the Lupus Pipeline Therapeutics Market with the market share of 65% in 2017 due to robust healthcare infrastructure and research and development activities in developed economies. North America holds the potential for Lupus pipeline therapeutics market as it is estimated that about 1.5 million Americans suffer from lupus.

Drivers & Challenges to Market Growth

According to the report, major driving factor for Lupus Pipeline Therapeutics Market is toxic effects of therapy in the past but recent improvements in care have dramatically enhanced the survival of Lupus patients. Inadequate current treatments and patients incompletely controlled disease, progression to end-stage organ involvement continues, and the therapies carry risks of debilitating side effects, making it important to facilitate the development of medical products that have the potential to be more effective and/or less toxic.   

Further, the report states that the major challenge is prolonged regulatory processes regarding the approval of biologic drugs as clinical testing is done in several phases, and this can take as much as 15 years. For instance, only belimumab has been approved as a biological therapy since 2011.

Covered In This Global Lupus Pipeline Therapeutics Market Report       

The report covers the present ground scenario and the future growth prospects of the Lupus Pipeline Therapeutics Market for 2017-2030 along with the prevalence of lupus worldwide along with the sales of drugs and pipeline products statistics with associated market player. We calculated the market size and revenue share on the basis of revenue generated from major players across the globe.

On the basis of lupus type, Lupus Nephritis (LN) leads the global Lupus Pipeline Therapeutics Market with the market share of 55% in 2017 due to its growing prevalence of lupus disease, launch of new biologic drugs and awareness among patients.             

Lupus Pipeline Therapeutics Market Outlook 2017-2030, has been prepared based on an in-depth market analysis from industry experts. The report covers the competitive landscape and current position of major players in the global Lupus Pipeline Therapeutics Market. The report also includes porter’s five force model, SWOT analysis, company profiling, business strategies of market players and their business models. Global Lupus Pipeline Therapeutics Market report also recognizes value chain analysis to understand the cost differentiation to provide competitive advantage to the existing and new entry players.

COVID-19 imapct on "Global Lupus Pipeline Therapeutics Market "    

Impact of COVID-19 Outbreak on “Global Lupus Pipeline Therapeutics Market ”, Manufacturers, Contract Manufacturers Suppliers and Recovery Strategy. A complete detailed chapter of 50-70 pages which includes the data and information focused on impacts of the pandemic on the Global Lupus Pipeline Therapeutics Market . It also showcases the expected recovery schedule and losses in the industry and other various major factors.

Key Players

AbbVie Inc, Asahi Kasei Pharma Corp.

Astellas Pharma Inc.

Aurinia Pharmaceuticals Inc

Azano Pharmaceuticals Inc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Deltanoid Pharmaceuticals Inc.

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline Plc

HanAll Biopharma Co.

Ltd., Invion Limited

KPI Therapeutics, Inc.

MedImmune LLC

Omeros Corporation

Ra Pharmaceuticals, Inc.

Resolve Therapeutics LLC

Takeda Pharmaceutical Company Limited

TxCell SA.

For a full detailed overview, send us the sample request.

Key questions answered in this Lupus Pipeline Therapeutics Market report

  • What is the total market size by 2030 and what would be the expected growth rate of Lupus Pipeline Therapeutics market?

  • What is the revenue of Lupus Pipeline Therapeutics in 2016-17 and what would be the expected demand over the forecast period?

  • What are the key market trends?

  • What are the factors which are driving this market?

  • What are the major barriers to market growth?

  • Who are the key vendors in this market space?

  • What are the market opportunities for the existing and entry level players?

  • What are the recent developments and business strategy of the key players?

We can provide two hour complimentary interaction with our analyst after the purchase of this market report. Details are imparted within the report.




{ }

Global Lupus Therapeutics Market Report by Product, by Distribution Channel, by Gender, & by Region With COVID-19 impact | Forecast Period 2017-2030

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

OR Call Us:+1-646-568-7747

Table of Contents

Please Select Linenece Type